To contribute to promotion of health and preservation of labor power of Korean laborers, the body height and body weight were measured for 10,407 workers (6,201 male, 4,206 female) in the age group of 20-29, engaged in manufactures in the Gumi industrial complex, Gumi city, Kyungpook province. The above data were extracted from the 1985 periodic examination chart for calculation of the mean body weight, mean body height, correlation coefficient and regression equation between weight and height, standard body weight, body mass index(BMI) and distribution of laborers within Garrow's classification of BMI by age and sex group. Mean body height of 20-29 age group was 168.2+/-5.61 cm for male and 155.9+/-5.26 cm for female. Mean body weight of 20-29 age group was 61.4+/-6.56 kg for male and 52.4+/-6.00 kg for female. Correlation coefficient and regression equation of 20-29 age group were +0.541 and Y(Wt)=0.632X(Ht)-44.975 for male and +0.559 and Y(Wt)=0.637X(Ht)-46.898 for female. Standard body weight of 20-29 age group was 53.0kg at 155cm, 59.3kg at 165cm, 65.6kg at 175cm for male and 51.8kg at 155cm, 58.2kg at 165cm, 64.6kg at 175 cm for female. Range of normal body weight of 20-29 age group was 47.5+/-58.5kg at 155cm, 53.8+/-64.8kg at 165cm, 60.1+/-72.1kg at 175cm for male and 46.9+/-56.8kg at 155cm, 53.2+/-63.2kg at 165cm, 59.6+/-69.6 kg at 175 cm for female. Range of obesity of 20-29 age group was 64.1kg and over at 155cm, 70.3kg and over at 165cm, 76.7kg and over at 175cm for male and 61.8kg and over at 155cm, 68.2kg and over at 165cm, 74.5kg and over at 175 cm for female. Body mass index (kg/m2) of 20-29 age group was 21.7+/-1.95 for male and 21.6+/-2.05 for female, 75.9% of male laborers and 71.3% of famale counterparts fall in the desirable range of BMI by Garrow's classification.
Body Height ; Body Mass Index ; Body Weight* ; Classification ; Female ; Gyeongsangbuk-do ; Health Promotion ; Humans ; Ideal Body Weight ; Male ; Obesity

Purpose: Targeted next-generation sequencing (NGS) panels for solid tumors have been useful in clinical framework for accurate tumor diagnosis and identifying essential molecular aberrations. However, most cancer panels have been designed to address a wide spectrum of pan-cancer models, lacking integral prognostic markers that are highly specific to gliomas. Materials and Methods: To address such challenges, we have developed a glioma-specific NGS panel, termed “GliomaSCAN,” that is capable of capturing single nucleotide variations and insertion/deletion, copy number variation, and selected promoter mutations and structural variations that cover a subset of intron regions in 232 essential glioma-associated genes. We confirmed clinical concordance rate using pairwise comparison of the identified variants from whole exome sequencing (WES), immunohistochemical analysis, and fluorescence in situ hybridization. Results: Our panel demonstrated high sensitivity in detecting potential genomic variants that were present in the standard materials. To ensure the accuracy of our targeted sequencing panel, we compared our targeted panel to WES. The comparison results demonstrated a high correlation. Furthermore, we evaluated clinical utility of our panel in 46 glioma patients to assess the detection capacity of potential actionable mutations. Thirty-two patients harbored at least one recurrent somatic mutation in clinically actionable gene. Conclusion We have established a glioma-specific cancer panel. GliomaSCAN highly excelled in capturing somatic variations in terms of both sensitivity and specificity and provided potential clinical implication in facilitating genome-based clinical trials. Our results could provide conceptual advance towards improving the response of genomically guided molecularly targeted therapy in glioma patients.